Harbour BioMed Appoints Immunology Research Leader
Kenneth M. Murphy, MD, PhD to its Scientific Advisory Board
(*Please scroll down for English news)
Kenneth M. Murphy博士
Murphy博士因其对免疫细胞遗传谱系分化及其可塑性的决定机制的研究而广受认可。他的实验室发现了多种控制T细胞、树突细胞与巨噬细胞分化的细胞因子和转录因子。他曾出版超过250篇学术刊著，在超过145场讲座上受邀演讲。他是《Immunity》、《International Immunology》、《European Journal of Immunology》等国际顶尖生物学术期刊的编委，同时还担任免疫学界的圣经《Janeway’s Immunobiology》一书的第一作者。他荣获众多权威奖项，其中包括美国纽约的癌症研究所为嘉奖其在基础免疫学领域的突出成就，而颁发的肿瘤免疫学界顶级大奖–威廉·科利奖。
Harbour BioMed Appoints Immunology Research Leader Kenneth M. Murphy, MD, PhD to its Scientific Advisory Board
Harbour BioMed (“HBM”) announced today the appointment of Kenneth M. Murphy, MD, PhD, to the company’s scientific advisory board. Dr. Murphy, a member of the National Academy of Sciences and a Howard Hughes Medical Institute Investigator, is the Eugene Opie First Centennial Professor of Pathology and Immunology at Washington University.
Dr Kenneth M. Murphy
“Dr Murphy is a distinguished immunologist with more than 30 years of expertise and experience in the field of immunology,” said Dr Jingsong Wang, HBM’s Founder, Chairman and CEO. “He brings to HBM great insight into basic mechanisms of immune cell lineage that underlie the immune response. We look forward to many contributions in guiding our programs aimed at developing next-generation therapeutics for cancer and immunological diseases.”
Dr Murphy is widely recognized for his research into the mechanisms of immune cell lineage differentiation and for determining the plasticity of these processes. His laboratory has discovered multiple cytokines and transcription factors that regulate differentiation of T cells, dendritic cells and macrophages.He is an author on 250 publications and delivered more than 145 invited lectureships. He serves in editorial capacities at several publications including, Immunity, International Immunology, and the European Journal of Immunology, and he is the lead author of Janeway’s Immunobiology. He received numerous awards, such as William B. Coley Award for Distinguished Research in Basic Immunology.
Dr Murphy has spent his career at Washington University. He joined the university faculty in 1989 after completing a post-doctoral fellowship and pathology residency at the school. Dr Murphy holds a combined M.D./Ph.D. degree from Johns Hopkins University.
About Harbour BioMed
Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology andinflammatory diseases. The company is building its proprietary pipeline throughinternal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.
The company’s discovery and development programs arecentered around its two patented transgenic mouse platforms for generating fully human monoclonal antibodies. Harbour BioMed also licenses the platformsto companies and academic institutions.The company has operations in Cambridge, Massachusetts; Rotterdam, TheNetherlands; and Shanghai, China. For more information, visit www.harbourbiomed.com.
PR Manager, Harbour BioMed